OptiBiotix Health - Director/PDMR Shareholding
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
Director/PDMR Shareholding
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitute, announces that the Company has been informed that David Blain, a Director of the Company, made the following purchase of ordinary shares in the capital of the Company.
Further details are set out in the Notification of Dealing Form below.
Director
Purchase price
Ordinary shares purchased
Resultant interest in ordinary shares
Resultant percentage of issued ordinary shares
David Blain
6.17 pence
158,965
243,018
0.24%
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
For further information, please contact: OptiBiotix Health plc
Neil Davidson, Chairman
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD and Broker)
Tel: 020 7213 0880
Liam Murray / Ludovico Lazzaretti / James Western
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has developed a range of technologies and commercialised products which modulate the human microbiome to help prevent and manage human disease. Since the Group's inception it has created a wide range of microbiome-based ingredients and products including prebiotic products like SlimBiome®, WellBiome®, SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc (OPTI) business, but also skincare through its holdings in SkinBioTherapeutics PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies create a diverse portfolio technologies and products in an emerging area of healthcare that is of growing interest in consumer markets throughout the world.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
David Blain
2
Reason for notification
a.
Position/Status
Finance Director
b.
Initial notification/
Amendment
Initial Notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
OptiBiotix Health Plc
b.
LEI
213800UKYQFT941QHS14
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification CodeOrdinary shares of 2p each
ISIN: GB00BP0RTP38
b.
Nature of the transaction
Purchase of ordinary shares
c.
Price(s) and volume(s)
Price(s) per share
Volume(s)
6.17 pence
158,965
d.
Aggregated information
- Volume
- Price
See above
e.
Date of the transaction
28 May 2026
f.
Place of the transaction
London Alternative Market (AIMX)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHSELEFAEMSEDI
